Head And Neck Squamous Cell Carcinoma
FDA grants fast track designation to NBTXR3 for head and neck cancer
The FDA granted fast track designation to NBTXR3, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell carcinoma who are not eligible for platinum-based chemotherapy, according to a company-issued press release.
Top stories in hematology/oncology: Closing cancer clinics increases health care spending, gene therapy ‘game changer’ for hemophilia A
Researchers found that increased travel time to cancer care sites due to clinic closings appeared to be associated with greater Medicare spending and patient costs — one of the top stories in hematology/oncology last week.
Pembrolizumab changes standard of care for recurrent, metastatic head and neck squamous cell carcinoma
Pembrolizumab in combination with platinum-based chemotherapy appeared to be a safe and effective first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma, according to results of the randomized phase 3 KEYNOTE-048 study published in The Lancet.